First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group.
Smith IE, et al.
Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.
Ann Oncol. 2011.
PMID: 20819780
Free article.
Clinical Trial.